ATE424827T1 - Zusammensetzung mit verzögerter freisetzung enthaltend lamotrigin - Google Patents

Zusammensetzung mit verzögerter freisetzung enthaltend lamotrigin

Info

Publication number
ATE424827T1
ATE424827T1 AT03766343T AT03766343T ATE424827T1 AT E424827 T1 ATE424827 T1 AT E424827T1 AT 03766343 T AT03766343 T AT 03766343T AT 03766343 T AT03766343 T AT 03766343T AT E424827 T1 ATE424827 T1 AT E424827T1
Authority
AT
Austria
Prior art keywords
composition containing
sustained release
release composition
containing lamotrigine
lamotrigine
Prior art date
Application number
AT03766343T
Other languages
English (en)
Inventor
Ian Buxton
Robin Currie
Myrna Dela-Cruz
Gary Goodson
Wlodzimierz Karolak
Mehran Maleki
Vijay Iyer
Gopal Muppirala
Alan Frank Parr
Jagdev Sidhu
Robert Stagner
Akunuri Vijay-Kumar
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0217492A external-priority patent/GB0217492D0/en
Priority claimed from GB0217493A external-priority patent/GB0217493D0/en
Priority claimed from GB0313801A external-priority patent/GB0313801D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE424827T1 publication Critical patent/ATE424827T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03766343T 2002-07-29 2003-07-28 Zusammensetzung mit verzögerter freisetzung enthaltend lamotrigin ATE424827T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0217492A GB0217492D0 (en) 2002-07-29 2002-07-29 Novel method of treatment
GB0217493A GB0217493D0 (en) 2002-07-29 2002-07-29 Novel methods of treatment
GB0313801A GB0313801D0 (en) 2003-06-13 2003-06-13 Novel methods of treatment

Publications (1)

Publication Number Publication Date
ATE424827T1 true ATE424827T1 (de) 2009-03-15

Family

ID=31499035

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03766343T ATE424827T1 (de) 2002-07-29 2003-07-28 Zusammensetzung mit verzögerter freisetzung enthaltend lamotrigin

Country Status (28)

Country Link
US (1) US20050032799A1 (de)
EP (1) EP1524981B1 (de)
JP (2) JP4744142B2 (de)
KR (1) KR100882707B1 (de)
CN (1) CN100363007C (de)
AR (1) AR040709A1 (de)
AT (1) ATE424827T1 (de)
AU (1) AU2003260336C1 (de)
BR (1) BRPI0313148B8 (de)
CA (1) CA2493301A1 (de)
CO (1) CO5680405A2 (de)
CY (1) CY1109119T1 (de)
DE (1) DE60326590D1 (de)
DK (1) DK1524981T3 (de)
ES (1) ES2323268T3 (de)
IL (1) IL166424A (de)
IS (1) IS2681B (de)
MA (1) MA27509A1 (de)
MX (1) MXPA05001243A (de)
MY (1) MY141049A (de)
NO (1) NO334221B1 (de)
NZ (1) NZ537885A (de)
PL (1) PL213565B1 (de)
PT (1) PT1524981E (de)
RU (1) RU2325163C2 (de)
SI (1) SI1524981T1 (de)
TW (1) TWI342213B (de)
WO (1) WO2004012741A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
CN100363007C (zh) * 2002-07-29 2008-01-23 葛兰素集团有限公司 含拉莫三嗪的缓释制剂
US20050169994A1 (en) * 2003-11-25 2005-08-04 Burke Matthew D. Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
US20060039975A1 (en) * 2004-08-20 2006-02-23 Zalman Vilkov Paroxetine formulations
JP5666087B2 (ja) * 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
WO2008109343A1 (en) * 2007-03-01 2008-09-12 Memory Pharmaceuticals Corporation Methods of treating bipolar disorder and memory and/or cognitive impairment associated therewith with (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate
US20090022789A1 (en) * 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
US8486927B2 (en) * 2007-11-09 2013-07-16 Thar Pharmaceuticals Crystalline forms of lamotrigine
US20090196924A1 (en) * 2008-02-04 2009-08-06 Pramod Kharwade Controlled-release lamotrigine formulations
AU2009270768A1 (en) * 2008-07-18 2010-01-21 Valeant Pharmaceuticals International Modified release formulation and methods of use
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
AU2010325960C1 (en) 2009-12-02 2015-08-06 Adamas Pharma, Llc Amantadine compositions and methods of use
WO2011086568A1 (en) * 2010-01-13 2011-07-21 Accutest Research Laboratories (I) Pvt. Ltd Controlled release composition for lamotrigine
MX2013008946A (es) * 2011-02-03 2013-10-25 Lupin Ltd Composiciones farmaceuticas orales de bepotastina de liberacion controlada.
WO2014159275A1 (en) * 2013-03-14 2014-10-02 PharmTak, Inc. Controlled-release pharmaceutical compositions comprising lamotrigine and methods of producing same
CN103920134A (zh) * 2014-05-08 2014-07-16 崔韡 一种治疗儿童眩晕的缓释片及其制备方法
RU2624229C2 (ru) * 2015-12-21 2017-07-03 Общество С Ограниченной Ответственностью "Валента-Интеллект" Таблетки клозапина с замедленным высвобождением и способ их получения
RU2613192C1 (ru) * 2016-02-18 2017-03-15 Общество С Ограниченной Ответственностью "Валента-Интеллект" Таблетки клозапина с пролонгированным высвобождением
US20200046716A1 (en) * 2017-02-03 2020-02-13 Jubilant Generics Limited Lamotrigine suspension dosage form
CN117860718A (zh) 2017-08-24 2024-04-12 阿达玛斯药物有限责任公司 金刚烷胺组合物、其制备和使用方法
SG11202003391XA (en) * 2017-10-27 2020-05-28 Chang Gung Memorial Hospital Linkou Method for assessing the risk of cutaneous adverse drug reactions induced by anti-epileptic drug lamotrigine, detection reagent thereof and use thereof
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
CN120168449A (zh) * 2018-04-25 2025-06-20 纽罗森特里亚股份有限公司 苏糖酸镁组合物及其用途
CN114948868B (zh) * 2021-04-16 2023-04-14 上海奥科达医药科技股份有限公司 一种拉莫三嗪水合物的晶体形式、其制备方法及包含其的组合物
CN116942606A (zh) * 2022-04-18 2023-10-27 上海奥科达医药科技股份有限公司 拉莫三嗪悬浮液和干混悬剂的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704295A (en) * 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
US4556552A (en) * 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
JPH0667828B2 (ja) * 1985-10-09 1994-08-31 日研化学株式会社 バルプロ酸ナトリウムの持続性顆粒製剤
US4775536A (en) * 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US4816262A (en) * 1986-08-28 1989-03-28 Universite De Montreal Controlled release tablet
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
IL91398A (en) * 1988-08-30 1994-05-30 Pfizer Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
DK0542364T3 (da) * 1991-11-13 1996-03-11 Glaxo Canada Anordning til reguleret frigivelse
IT1266565B1 (it) * 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
US5733575A (en) * 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
CA2264182A1 (en) * 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
GB9625795D0 (en) * 1996-12-12 1997-01-29 Smithkline Beecham Plc Novel treatment
US6046716A (en) * 1996-12-19 2000-04-04 Colorado Microdisplay, Inc. Display system having electrode modulation to alter a state of an electro-optic layer
CA2216215A1 (en) * 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
GB9726987D0 (en) * 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
EP1652516A3 (de) * 1998-11-02 2006-05-17 ALZA Corporation Osmotisch kontrollierte Freigabe von Wirkstoffen
GB9930079D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
GB0024517D0 (en) * 2000-10-06 2000-11-22 Glaxo Group Ltd Use of medicaments
DE10224170A1 (de) * 2002-05-31 2003-12-11 Desitin Arzneimittel Gmbh Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
CN100363007C (zh) * 2002-07-29 2008-01-23 葛兰素集团有限公司 含拉莫三嗪的缓释制剂

Also Published As

Publication number Publication date
BRPI0313148B1 (pt) 2019-08-20
CA2493301A1 (en) 2004-02-12
IS2681B (is) 2010-09-15
JP4744142B2 (ja) 2011-08-10
EP1524981B1 (de) 2009-03-11
JP2011057683A (ja) 2011-03-24
MA27509A1 (fr) 2005-09-01
TWI342213B (en) 2011-05-21
AU2003260336A1 (en) 2004-02-23
JP2005538113A (ja) 2005-12-15
NO334221B1 (no) 2014-01-13
PL213565B1 (pl) 2013-03-29
KR20050026054A (ko) 2005-03-14
PL374982A1 (en) 2005-11-14
HK1077003A1 (en) 2006-02-03
MXPA05001243A (es) 2005-06-08
MY141049A (en) 2010-02-25
IL166424A (en) 2010-12-30
WO2004012741A1 (en) 2004-02-12
AU2003260336C1 (en) 2008-05-29
CN100363007C (zh) 2008-01-23
KR100882707B1 (ko) 2009-02-06
NZ537885A (en) 2007-11-30
TW200418484A (en) 2004-10-01
CY1109119T1 (el) 2014-07-02
AR040709A1 (es) 2005-04-13
EP1524981A1 (de) 2005-04-27
RU2325163C2 (ru) 2008-05-27
SI1524981T1 (sl) 2009-08-31
CO5680405A2 (es) 2006-09-29
IL166424A0 (en) 2006-01-15
NO20050948L (no) 2005-02-22
US20050032799A1 (en) 2005-02-10
BR0313148A (pt) 2005-07-12
BRPI0313148B8 (pt) 2021-05-25
DE60326590D1 (de) 2009-04-23
IS7707A (is) 2005-02-23
ES2323268T3 (es) 2009-07-10
DK1524981T3 (da) 2009-06-22
PT1524981E (pt) 2009-06-17
CN1681509A (zh) 2005-10-12
RU2005105353A (ru) 2005-10-27

Similar Documents

Publication Publication Date Title
DE60325255D1 (de) Duftzusammensetzung
EP1537195A4 (de) Desinfizierende zusammensetzung
EP1561476A4 (de) Desodorierende zusammensetzung
DE10393374D2 (de) Zusammensetzung
DK3473251T3 (da) Nikotin-cellulose-kombination
ATE368042T1 (de) Cephemverbindungen
EP1531670A4 (de) Herbizidzusammensetzung
NO20044046L (no) Substituerte hydroksyetylaminer
DE50311358D1 (de) Bimetall-Sägeband
EP1559433A4 (de) Stabilisierte zusammensetzung
DK1524981T3 (da) Sammensætninger med vedvarende frigivelse indeholdende lamotrigin
DE60228702D1 (de) Waschmittelzusammensetzung
IS7381A (is) Efnasambönd
DK1561472T3 (da) Faststofsammensætning
IS7414A (is) Oxó-azabísýklísk efnasambönd
DE60310914D1 (de) Pulverzusammensetzung
DE60320902D1 (de) Zusammensetzungen mit ausgelöster Freisetzung
EP1578758A4 (de) Purinnukleoside
NO20045659L (no) Forbindelser
SE0500163L (sv) Sammansättning
ATE496887T1 (de) Substituierte 5-aminomethyl-1h-pyrrol-2-carbons ureamide
DE50303792D1 (de) Fixiereinlage
EP1500603A4 (de) Ausgiessbehälter
NO20044337L (no) Faststoff-dispergeringspreparat
DE60326900D1 (de) Duftstoff-Zusammensetzung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1524981

Country of ref document: EP